Abbott Sees ABSORB Coronary Stent Study Enrollment Complete

Abbott has announced the completion of enrollment of three clinical trials to support approvals of the company’s revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China.

Background

Abbott leads the market in developing and commercializing a drug-eluting BVS for blocked heart vessels, its Absorb now being available in more than 60 countries around the world.

Unlike a metallic stent, Absorb dissolves over time, the aim being to restore a naturally flexible vessel, free from a permanent metallic stent. Unlike a metallic stent, which is a permanent implant, Abbott refers to Absorb as a scaffold, indicating its temporary nature. Absorb is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures.

The ABSORB III clinical trial, which enrolled approximately 2,000 people in the United States, will evaluate the potential benefits of Absorb in people with coronary artery disease, a narrowing of one or more arteries that supply blood to the heart. The primary endpoint of ABSORB III is target lesion failure (TLF), a combined measure of the safety and effectiveness of Absorb in comparison to the company’s XIENCE family of drug eluting stents at one year.

The ABSORB Japan and ABSORB China trials enrolled approximately 400 people each, and the primary endpoint is TLF at one year and late loss at one year, respectively, in comparison to the XIENCE family of drug eluting stents. The ABSORB II trial enrolled approximately 500 people, mostly in Europe, and one-year clinical results are anticipated later this year.

Investigator comments

“The rapid completion of enrollment in the Absorb randomized trials is a testament to the interest among doctors and patients in advancing new options to treat heart disease,” said Gregg Stone, M.D., FACC, FSCAI, director, cardiovascular research and education, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York-Presbyterian Hospital. “Absorb represents an entirely new approach to helping people with heart disease by doing the job of a metallic stent, but then disappearing after its work is done, giving people the opportunity to live their lives free of a permanent metallic device implanted in their arteries.”

“The medical community eagerly awaits the results of the randomized trials for Absorb,” said Dean Kereiakes, M.D., FACC, FSCAI, medical director of The Christ Hospital Heart & Vascular Center and the Lindner Research Center in Cincinnati, and professor of clinical medicine at Ohio State University. “We have made tremendous progress in interventional cardiology with the advances in metallic stents. A device that could provide similar benefits but not leave behind a permanent implant has the potential to transform the way coronary artery disease is treated.”

Company comments 

“The randomized clinical trials for Absorb demonstrate Abbott’s commitment to provide the highest level of clinical evidence possible to assess Absorb compared to metallic drug eluting stents – the current standard of care,” said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. “We look forward to evaluating the results of these trials, which we intend to submit to support regulatory approvals of the device.”

Source: Abbott Vascular

Share your thoughts

Your email address will not be published. Required fields are marked *